IPOS COPY
2000 00058-8

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 39/00

A2

(11) International Publication Number: WO 99/04810

(43) International Publication Date: 4 February 1999 (04.02.99)

(21) International Application Number: PCT/EP98/04621

(22) International Filing Date: 23 July 1998 (23.07.98)

(30) Priority Data:
97401800.4 25 July 1997 (25.07.97) EP

(71) Applicants *(for all designated States except US)*: INSTITUT GUSTAVE ROUSSY [FR/FR]; 39, rue Camille Desmoulins, F-94805 Villejuif Cedex (FR). APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. [NL/NL]; John R. Gorsiraweg 6, P.O. Box 3889, Curaçao (AN).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: TRIEBEL, Frédérique [FR/FR]; 10, rue Saint-Louis, F-78000 Versailles (FR).

(74) Agent: HIRSCH, Denise; Cabinet Lavoix, 2, place d'Estienne d'Orves, F-75441 Paris Cedex 09 (FR).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: USE OF MHC CLASS II LIGANDS AS ADJUVANT FOR VACCINATION AND OF LAG-3 IN CANCER TREATMENT

(57) Abstract

The present invention concerns a use of a MHC class II ligand, such as CD4 and LAG-3, for the manufacture of a medicament for preventing or treating pathological conditions involving an antigen specific immune response, as well as the use of LAG-3 in cancer-immunotherapy. The invention also concerns a pharmaceutical composition comprising an effective amount of an antigen able to induce an antigen-specific immune response together with an effective amount of a MHC class II ligand wherein said MHC class II ligand is present as an adjuvant-like agent.